SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the license of its "insert and rotate" method technology to Theken Spine, LLC.
Under the agreement, Theken Spine was granted a non-exclusive license to use NuVasive's patented "insert and rotate" method of US Patent No. 6,290,724 in exchange for royalty payments to be made to NuVasive. The patented "insert and rotate" method is a means of inserting a device between adjacent vertebrae and then rotating the device for the purpose of separating and stabilizing those vertebrae.
Commenting on the patent license agreement, Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "We view this license arrangement as a solid validation of our unique and growing Intellectual Property platform. We commend Theken Spine for their cooperation in working to conclude this agreement."
About NuVasive
NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.
The MAS platform offers advantages for both patients and surgeons such
as reduced surgery and hospitalization time and faster recovery. MAS
combines three categories of current product offerings: NeuroVision a
proprietary software-driven nerve avoidance system; MaXcess(R) a unique
split-blade design retraction system; and specialized implants, like
SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption
during spine surgery while allowing maximum visualization
'/>"/>
| SOURCE NuVasive, Inc. Copyright©2007 PR Newswire. All rights reserved |